FDA Approves Third Sarepta Treatment For Duchenne Muscular Dystrophy

The U.S. Food and Drug Administration (FDA) approved Sarepta Therapeutics’ Amondys 45 (casimersen) for patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation amenable to exon 45 skipping.

DMD is a muscle-wasting disease caused by mutations in the dystrophin gene. This results in a decreased or lack of the muscle protein dystrophin.